Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
16 mai 2022 08h30 HE
|
Vyant Bio, Inc.
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights ●Progress in the discovery of small molecule therapeutics to treat neurodevelopmental and...
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
30 mars 2022 07h50 HE
|
Vyant Bio, Inc.
Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative...
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
19 août 2021 09h27 HE
|
Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...